Abstract
This commentary re-examines a recent article by Labonté et al on the recent changes to two relevant provisions relating to patent rights in the final version of the United-States-Mexico-Canada Agreement (USMCA). Although the USMCA’s final revised version does not add more pharmaceutical patent protection than those that already exist in the three trading partners, the agreement has done little to enhance access to generic medicines and biosimilars.
| Original language | English |
|---|---|
| Article number | 50 |
| Number of pages | 2 |
| Journal | Globalization and Health |
| Volume | 16 |
| Online published | 5 Jun 2020 |
| DOIs | |
| Publication status | Published - 2020 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 10 Reduced Inequalities -
SDG 17 Partnerships for the Goals
Research Keywords
- Public health
- USMCA
- Pharmaceutical patent
- Biologics
Publisher's Copyright Statement
- This full text is made available under CC-BY 4.0. https://creativecommons.org/licenses/by/4.0/
Fingerprint
Dive into the research topics of 'Revisiting the public health implications of the United States–Mexico– Canada agreement'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver